<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT04416672</url>
  </required_header>
  <id_info>
    <org_study_id>VIP</org_study_id>
    <nct_id>NCT04416672</nct_id>
  </id_info>
  <brief_title>Validation of the Italian Version of the PRO-CTCAE</brief_title>
  <official_title>VIP: Validation of the Italian Version of the Patient-Reported Outcomes - Common Terminology Criteria for Adverse Events (PRO-CTCAE): A Prospective Multicenter Observational Study on Different Cancer Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Naples</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Naples</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to complete the validation process by testing the remaining two&#xD;
      psychometric properties (validity and responsiveness) of the Italian version of the PRO-CTCAE&#xD;
      in a large group of patients. In particular, for the first time this study will validate the&#xD;
      tool for individual types of cancer and will provide information on psychometric properties&#xD;
      based on the type of treatment used in clinical practice.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a prospective observational study, conducted in Italian cancer centers located&#xD;
      Nationwide.&#xD;
&#xD;
      The investigators plan to consider for validation 21tumor sites, which correspond to the&#xD;
      conditions for which a specific EORTC module has been produced, plus all remaining cancer&#xD;
      types classified as &quot;other setting&quot;.&#xD;
&#xD;
      The study will take place during two planned visits, one the first the day of enrollment, the&#xD;
      second after 3-6 weeks. Enrolled patients will be asked to complete a subset of the PRO-CTCAE&#xD;
      items based on cancer type, and the following instruments used as anchors to measure&#xD;
      psychometric properties:&#xD;
&#xD;
        -  EORTC Quality of Life disease-specific module, if a linguistically validated Italian&#xD;
           version exists, or the General QLQ-C30, if the Italian version is not available.&#xD;
&#xD;
        -  the Hospital Anxiety and Depression Scale (HADS)&#xD;
&#xD;
        -  The Patients' Global Impression of Change (PGIC) Scale&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2018</start_date>
  <completion_date type="Anticipated">July 2024</completion_date>
  <primary_completion_date type="Anticipated">July 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validity of the italian version of the PRO-CTCAE</measure>
    <time_frame>at baseline (up to 3weeks)</time_frame>
    <description>Evaluation of the validity (degree to which an instrument accurately measures the underlying phenomenon) of single items of the PRO-CTCAE, Italian version, for each of the type of cancer considered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Validity of the italian version of the PRO-CTCAE</measure>
    <time_frame>at 3 weeks (up to 6 weeks)</time_frame>
    <description>Evaluation of the validity (degree to which an instrument accurately measures the underlying phenomenon) of single items of the PRO-CTCAE, Italian version, for each of the type of cancer considered</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responsiveness of the italian version of the PRO-CTCAE</measure>
    <time_frame>at baseline (up to 3 weeks)</time_frame>
    <description>Evaluation of responsiveness (ability of an instrument to show a change when there has been a change in the phenomenon) of single items of the PRO-CTCAE for each of the types of cancer considered.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Responsiveness of the italian version of the PRO-CTCAE</measure>
    <time_frame>at 3 weeks (up to 6 weeks)</time_frame>
    <description>Evaluation of responsiveness (ability of an instrument to show a change when there has been a change in the phenomenon) of single items of the PRO-CTCAE for each of the types of cancer considered.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Differences in psychometric measures according to tumor type and treatment</measure>
    <time_frame>at 3 weeks (up to 6 weeks)</time_frame>
    <description>Evaluate any differences in psychometric measures according to:&#xD;
type of cancer (breast, lung, liver ...)&#xD;
type of treatment (chemotherapy, hormone therapy, immunotherapy, ...)</description>
  </secondary_outcome>
  <enrollment type="Anticipated">3675</enrollment>
  <condition>Malignant Neoplasms</condition>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>PRO-CTCAE items</intervention_name>
    <description>Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:&#xD;
the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.&#xD;
the Hospital Anxiety and Depression Scale (HADS)&#xD;
The Patients' Global Impression of Change (PGIC) Scale.</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Any type of cancer&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any type of cancer&#xD;
&#xD;
             •≥18 years of age.&#xD;
&#xD;
          -  Female or male&#xD;
&#xD;
          -  With at least two planned clinic visits (a return visit within 3-6 weeks) to avoid the&#xD;
             need of extra visits&#xD;
&#xD;
          -  Actively receiving treatment for cancer (going to receive the second or further cycle)&#xD;
&#xD;
          -  Any ECOG performance status (PS)&#xD;
&#xD;
          -  Able to complete questionnaire by themselves or with assistance, by using a tablet&#xD;
&#xD;
          -  Able to speak and understand Italian&#xD;
&#xD;
          -  Providing informed written consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Having any kind of psychiatric disorder or major cognitive dysfunction hampering the&#xD;
             provision of informed consent.&#xD;
&#xD;
          -  Having received more than 5lines of therapies&#xD;
&#xD;
          -  Currently participating in other trials which imply the completion of Patient Reported&#xD;
             Outcomes (PROs) in the same period&#xD;
&#xD;
          -  Other important acute medical conditions.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Francesco Perrone, MD, PhD</last_name>
    <phone>+390815903571</phone>
    <phone_ext>+390815903571</phone_ext>
    <email>f.perrone@istitutotumori.na.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Oncologia Medica per la Patologia Toracica- IRCCS Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Galetta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Domenico Galetta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. Oncologia Medica - Ospedale Senatore Antonio Perrino</name>
      <address>
        <city>Brindisi</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Saverio Cinieri, MD</last_name>
    </contact>
    <investigator>
      <last_name>Saverio Cinieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero Universitaria di Cagliar</name>
      <address>
        <city>Cagliari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alberto Sobrero, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica 2 - IRCCS AOU San Martino</name>
      <address>
        <city>Genova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lucia Del Mastro, MD</last_name>
    </contact>
    <investigator>
      <last_name>Lucia Del Mastro, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia - A.O. Cardinale G. Panico</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Emiliano Tamburini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Emiliano Tamburini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - AO Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvana Leo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Silvana Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica, Istituto Romagnolo per lo Studio e la Cura dei Tumori</name>
      <address>
        <city>Meldola</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ugo De Giorgi, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Ugo De giorgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O.Ospedali Riuniti Papardo Piemonte U.O.C. di Oncologia Medica</name>
      <address>
        <city>Messina</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Adamo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vincenzo Adamo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS, Istituto Nazionale dei Tumori</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carla Ida Ripamonti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Carla Ida Ripamonti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ginecologia e Ostetricia - IRCCS Ospedale San Raffaele</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alice Bergamini, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alice Bergamini, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia - ASST Rhodense - Presidio di Garbagnat</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Silvia Della Torre, MD</last_name>
    </contact>
    <investigator>
      <last_name>Silvia Della Torre, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia - ASST Rhodense - Presidio di Rho</name>
      <address>
        <city>Milan</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sara Di Bella, MD</last_name>
    </contact>
    <investigator>
      <last_name>Sara Di Bella, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori, Dip. Uro-Ginecologico S.C. Oncologia Clinica Sperimentale Uro-Ginecologica</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sandro Pignata, MD, PhD</last_name>
    </contact>
    <investigator>
      <last_name>Sandro Pignata, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica Toraco-Polmonare -Istituto Nazionale Tumori</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alessandro Morabito, MD</last_name>
    </contact>
    <investigator>
      <last_name>Alessandro Morabito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Servizio di Oncologia Medica ed Ematologia - DAI di Internistica Polispecialistica- AOU Università degli studi della Campania &quot;Luigi Vanvitelli&quot;</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michele Orditura, MD</last_name>
    </contact>
    <investigator>
      <last_name>Michele Orditura, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Struttura semplice Sarcomi ossa e tessuti molli, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale</name>
      <address>
        <city>Naples</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonio Pizzolorusso, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonio Pizzolorusso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>U.O.C. di Oncologia - Presidio Monaldi - AORN Ospedale dei Colli</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincenzo Montesarchio, MD</last_name>
      <phone>+390817065268</phone>
      <email>vincenzo.montesarchio@ospedaledeicolli.it</email>
    </contact>
    <investigator>
      <last_name>Vincenzo Montesarchio, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vittorina Zagonel, MD</last_name>
    </contact>
    <investigator>
      <last_name>Vittorina Zagonel, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AOU Oncologia Medica</name>
      <address>
        <city>Parma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marcello Tiseo, MD</last_name>
    </contact>
    <investigator>
      <last_name>Marcello Tiseo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia traslazionale - ICS Maugeri di Pavia</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Camillo Porta, MD</last_name>
    </contact>
    <investigator>
      <last_name>Camillo Porta, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica ed Ematologia, USL di Piacenza - Ospedale Guglielmo da Saliceto</name>
      <address>
        <city>Piacenza</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica 2 - Istituto Nazionale Tumori &quot;Regina Elena&quot;</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Patrizia Vici, MD</last_name>
    </contact>
    <investigator>
      <last_name>Patrizia Vici, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UOC Oncologia Medica 1 - Istituti Fisioterapici Ospitalieri - Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Antonella Savarese, MD</last_name>
    </contact>
    <investigator>
      <last_name>Antonella Savarese, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia - Ospedale S. G. Moscati</name>
      <address>
        <city>Taranto</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Salvatore Pisconti, MD</last_name>
    </contact>
    <investigator>
      <last_name>Salvatore Pisconti, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Oncologia Medica - Istituto Sacro Cuore Don Calabria</name>
      <address>
        <city>Verona</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefania Gori, MD</last_name>
    </contact>
    <investigator>
      <last_name>Stefania Gori, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>May 29, 2020</study_first_submitted>
  <study_first_submitted_qc>June 3, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 4, 2020</study_first_posted>
  <last_update_submitted>March 23, 2023</last_update_submitted>
  <last_update_submitted_qc>March 23, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">March 24, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>PRO-CTCAE</keyword>
  <keyword>EORTC QLQ-C30 or Disease-Specific Questionnaire</keyword>
  <keyword>HADS</keyword>
  <keyword>PGIC Scale</keyword>
  <keyword>Performance Status</keyword>
  <keyword>Quality of Life</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT04416672
org study id: VIP
nct id: NCT04416672
lead sponsor: 
has dmc: Yes
is fda regulated drug: No
is fda regulated device: No
The aim of this study is to complete the validation process by testing the remaining two
      psychometric properties (validity and responsiveness) of the Italian version of the PRO-CTCAE
      in a large group of patients. In particular, for the first time this study will validate the
      tool for individual types of cancer and will provide information on psychometric properties
      based on the type of treatment used in clinical practice.
This is a prospective observational study, conducted in Italian cancer centers located
      Nationwide.

      The investigators plan to consider for validation 21tumor sites, which correspond to the
      conditions for which a specific EORTC module has been produced, plus all remaining cancer
      types classified as "other setting".

      The study will take place during two planned visits, one the first the day of enrollment, the
      second after 3-6 weeks. Enrolled patients will be asked to complete a subset of the PRO-CTCAE
      items based on cancer type, and the following instruments used as anchors to measure
      psychometric properties:

        -  EORTC Quality of Life disease-specific module, if a linguistically validated Italian
           version exists, or the General QLQ-C30, if the Italian version is not available.

        -  the Hospital Anxiety and Depression Scale (HADS)

        -  The Patients' Global Impression of Change (PGIC) Scale
observational model: Other
time perspective: Prospective
measure: Validity of the italian version of the PRO-CTCAE
time frame: at baseline (up to 3weeks)
description: Evaluation of the validity (degree to which an instrument accurately measures the underlying phenomenon) of single items of the PRO-CTCAE, Italian version, for each of the type of cancer considered
measure: Validity of the italian version of the PRO-CTCAE
time frame: at 3 weeks (up to 6 weeks)
description: Evaluation of the validity (degree to which an instrument accurately measures the underlying phenomenon) of single items of the PRO-CTCAE, Italian version, for each of the type of cancer considered
measure: Responsiveness of the italian version of the PRO-CTCAE
time frame: at baseline (up to 3 weeks)
description: Evaluation of responsiveness (ability of an instrument to show a change when there has been a change in the phenomenon) of single items of the PRO-CTCAE for each of the types of cancer considered.
measure: Responsiveness of the italian version of the PRO-CTCAE
time frame: at 3 weeks (up to 6 weeks)
description: Evaluation of responsiveness (ability of an instrument to show a change when there has been a change in the phenomenon) of single items of the PRO-CTCAE for each of the types of cancer considered.
measure: Differences in psychometric measures according to tumor type and treatment
time frame: at 3 weeks (up to 6 weeks)
description: Evaluate any differences in psychometric measures according to:
type of cancer (breast, lung, liver ...)
type of treatment (chemotherapy, hormone therapy, immunotherapy, ...)
intervention type: Other
intervention name: PRO-CTCAE items
description: Enrolled patients will be asked to complete a subset of the PRO-CTCAE items based on cancer type, and the following instruments used as anchors to measure psychometric properties:
the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life disease-specific module, if a linguistically validated Italian version exists, or the General QLQ-C30, if the Italian version is not available.
the Hospital Anxiety and Depression Scale (HADS)
The Patients' Global Impression of Change (PGIC) Scale.
study pop: 
sampling method: Probability Sample
criteria: 
gender: All
minimum age: 18 Years
maximum age: N/A
healthy volunteers: No
last name: Francesco Perrone, MD, PhD
role: Principal Investigator
affiliation: Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale
last name: Francesco Perrone, MD, PhD
phone: +390815903571
phone ext: +390815903571
email: f.perrone@istitutotumori.na.it
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
facility: 
status: Recruiting
contact: 
investigator: 
country: Italy
responsible party type: Sponsor
mesh term: Neoplasms
sharing ipd: No